CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials.
about
Screening and identification of novel biologically active natural compounds.Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology.MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies.Genetic compensation: A phenomenon in search of mechanisms.Genetic modifiers as relevant biological variables of eye disorders.MELK is not necessary for the proliferation of basal-like breast cancer cells.Up-Regulated Maternal Embryonic Leucine Zipper Kinase Predicts Poor Prognosis of Hepatocellular Carcinoma Patients in a Chinese Han Population.The target landscape of clinical kinase drugs.MELK is a novel therapeutic target in high-risk neuroblastoma.MELK expression correlates with tumor mitotic activity but is not required for cancer growth.Identification of potential therapeutic targets in prostate cancer through a cross-species approach.Challenges in validating candidate therapeutic targets in cancer.While it is not deliberate, much of today's biomedical research contains logical and technical flaws, showing a need for corrective action.Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity on multiple myeloma bone disease.Correction: MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells.Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.Gene editing in the context of an increasingly complex genomeA Conditional Dependency on MELK for the Proliferation of Triple-Negative Breast Cancer Cells
P2860
Q33777835-0DADED22-FD81-4CEB-BCBD-312307D53C5EQ33906319-722AA459-8842-458A-9047-B6CBD0DD7B7CQ38648606-A4B5DC21-3453-4C53-99B4-3DCE3D5C6A1BQ38680916-09CCBDFE-8B24-49EA-A0D9-BB702E5C4CE1Q39290939-ADAE746B-123A-4E30-9BF3-36B2D626034EQ41705554-DDF2966C-2696-42E5-9FE1-0E41DB260477Q47153156-3403776B-A027-4041-B0B8-BE043AB1DB74Q47345032-5AC0F7E4-FDA9-4E67-9A0B-898FD962E687Q49187608-491627BA-B79E-48B6-AE93-AA69F6E22D50Q49701324-A149D3C9-F910-4F16-996A-EA240EB91851Q50043890-F32BBEA2-0228-43B7-BD84-0BB7CF8F1A1FQ50123858-A3AFE90B-8B64-467F-AD9E-640789992BBFQ52671014-EE289AAA-D26F-4A90-B673-C73E36F48BC3Q54110801-7A87269A-2CDE-49C1-B36D-330C17C0CD04Q54121880-97A1F066-7CD3-4477-B993-397AEA7FA8B3Q55129685-98421C35-17DF-4094-95C7-9DE0655183B7Q57170220-D14E532B-BB1A-43B6-9BE4-A32572BE9315Q58597498-61A38636-C962-4EEA-8354-FEDDBCEED8F8
P2860
CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
CRISPR/Cas9 mutagenesis invali ...... d in on-going clinical trials.
@en
CRISPR/Cas9 mutagenesis invali ...... d in on-going clinical trials.
@nl
type
label
CRISPR/Cas9 mutagenesis invali ...... d in on-going clinical trials.
@en
CRISPR/Cas9 mutagenesis invali ...... d in on-going clinical trials.
@nl
prefLabel
CRISPR/Cas9 mutagenesis invali ...... d in on-going clinical trials.
@en
CRISPR/Cas9 mutagenesis invali ...... d in on-going clinical trials.
@nl
P2093
P2860
P50
P356
P1433
P1476
CRISPR/Cas9 mutagenesis invali ...... d in on-going clinical trials.
@en
P2093
Christopher J Giuliano
Jason M Sheltzer
Nicole M Sayles
P2860
P356
10.7554/ELIFE.24179
P407
P577
2017-03-24T00:00:00Z